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Rap1We have generated mouse transgenic lineages for C3G (tgC3G) and C3GΔCat (tgC3GΔCat, C3G mutant lac-
king the GEF domain), where the transgenes are expressed under the control of the megakaryocyte and
platelet speciﬁc PF4 (platelet factor 4) gene promoter. Transgenic platelet activity has been analyzed through
in vivo and in vitro approaches, including bleeding time, aggregation assays and ﬂow cytometry. Both trans-
genes are expressed (RNA and protein) in puriﬁed platelets and megakaryocytes and do not modify the num-
ber of platelets in peripheral blood. Transgenic C3G animals showed bleeding times signiﬁcantly shorter than
control animals, while tgC3GΔCat mice presented a remarkable bleeding diathesis as compared to their con-
trol siblings. Accordingly, platelets from tgC3G mice showed stronger activation in response to platelet ago-
nists such as thrombin, PMA, ADP or collagen than control platelets, while those from tgC3GΔCat animals had
a lower response. In addition, we present data indicating that C3G is a mediator in the PKC pathway leading
to Rap1 activation. Remarkably, a signiﬁcant percentage of tgC3Gmice presented a higher level of neutrophils
than their control siblings. These results indicate that C3G plays an important role in platelet clotting through
a mechanism involving its GEF activity and suggest that it might be also involved in neutrophil development.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Rap1 is a small GTPase of the Ras family that is ubiquitously
expressed [1]. Many studies support a role for the Rap1 isoform
Rap1b (but not Rap1a) in critical aspects of platelet function, includ-
ing aggregation, coagulation, adhesion and spreading, through the
platelet integrin αIIbβ3 [2,3]. Rap1b is highly expressed in mature
megakaryocytes and platelets, accounting for about 0.1% of thequímica y Biología Molecular II,
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l rights reserved.total cellular proteins [3]. Recently, genetic evidences have demon-
strated that Rap1b is involved in a common crucial step required
for platelet activation [4]. Rap1b participates in the responses trig-
gered by most platelet agonists, including ADP, collagen, epineph-
rine, thrombin and PMA [4–6]. In particular, ADP, thrombin and
PMA activate platelet Rap1b through pathways involving an in-
crease in intracellular calcium via Gαq-mediated PLC activation [2].
Rap1b can also be activated by Ca2+-independent mechanisms in-
volving Gαi/Gαz signaling and the subsequent activation of PI3K
[7–9].
Rap proteins are activated upon binding to GTP, which is stimulated
by guanine nucleotide exchange factors (GEFs) [3]. The RapGEFs de-
scribed to have a signiﬁcant expression in human platelets are
CalDAG-GEFI/RasGRP2, CalDAG-GEFIII/RasGRP3 and PDZ-GEF1 [10,11].
In mouse platelets, the most relevant Rap1 GEF described so far is
CalDAG-GEFI, whose function is crucial for signal integration in plate-
lets. Mouse platelets lacking CalDAG-GEFI are severely compromised
in the integrin-dependent aggregation as a consequence of their
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Rap1 activation has been described in response to thrombin [5,14].
C3G is a Rap1/2 GEF that regulates Rap activation by tyrosine kinases
[1,3]. C3G-mediated Rap1 activation plays critical roles in adhesion. In
fact, C3G-dependent Rap1 activation is essential during early mouse
embryogenesis due to its role in integrin- and paxillin‐mediated cellular
adhesion and spreading [15]. Moreover, C3G is required for the forma-
tion and stabilization of integrin β1- and paxillin-positive focal adhe-
sions [16]. C3G is also an essential activator of Rap1 during junction
formation, both in epithelial and endothelial cells [17]. In addition,
C3G has been implicated in Rap1-dependent adhesion in many
hematopoietic-cell types [18,19]. Based on the critical role of C3G in ad-
hesion processes regulated by Rap1, we can hypothesize that C3G,
which is expressed at low level inmouse platelets [20], could participate
in Rap1-mediated platelet functions. This is supported by previous data
showing the involvement of C3G in thrombopoietin (TPO)-mediated
Rap1 activation during megakaryocytic differentiation to platelets [3].
TPO binding to the MpI receptor induces CrkL phosphorylation and
the recruitment of a Cbl/CrkL/C3G complex, which results in the
sustained activation of ERKs [21].
Rap1 is rapidly activated after stimulation of human platelets with
α-thrombin. Phospholipase C-mediated increase in intracellular calci-
um is necessary and sufﬁcient for this activation, which suggests the
participation of CalDAG-GEFs [5,22]. Nevertheless, thrombin induces
a second peak of Rap1 activation, which is mediated by protein kinase
C (PKC), but independent of Ca2+ and CalDAG-GEF [5,14]. The specif-
ic components of this second pathway, and in particular, the speciﬁc
GEF that contributes to the second wave of Rap1 activation has not
been identiﬁed so far.
To examinewhether C3Gmight play a role in platelet functions, we
have generated C3G and C3GΔCat (C3G mutant with a deletion in the
GEF domain) transgenic mice with speciﬁc protein over-expression in
megakaryocytes and platelets. In vivo and in vitro experiments re-
vealed a higher activation and aggregation of C3G transgenic platelets
than those from wild type animals. In contrast, platelets expressing
the C3GΔCat mutant showed impaired activation and aggregation.
Thus, our results indicate that the manipulation of C3G expression
modiﬁes platelet responses and therefore, it could play an important
role as a therapeutical target in thrombotic disorders through the
modulation of Rap1 activity. Unexpectedly, C3G transgenic mice
have a signiﬁcant higher number of neutrophils than control mice,
suggesting a possible C3G function in neutrophil development.
1.1. Research ethics
This study was carried out in strict accordance with the EU Directive
2010/63/EU for animal experiments http://ec.europa.eu/environment/
chemicals/lab_animals/legislation_en.htm and Uniform Requirements
for manuscripts submitted to Biomedical journals http://www.icmje.org.
The protocol was approved by the Committee on the Ethics of
Animal Experiments of the University of Salamanca, ID number:
SAF2010-20918-C02-02. All surgeries were performed under ketamine
anesthesia, and all efforts were made to minimize suffering.
2. Materials and methods
2.1. Genetic engineering of plasmids PF4-C3G-LN and PF4-C3GΔCat-LN
A BamHI fragment containing human C3G gene was excised from
pLTR2C3G construct [23] and cloned into pBluescript SK+ (Strata-
gene) previously modiﬁed by in vitro mutagenesis to create a NcoI
site (pBluescriptSK-NcoI), using oligonucleotides pSKNcoI-F (5′-
TGCATATCAAGCTTATCGATACCATGGACCTCGAGG-′3) and pSKNcoI-R
(5′-CCTCGAGGTCCATGGTATCGATAAGCTTGATATCGA-′3). The resulting
construct was named pSKNco-C3G. PF4-Globin vector, containing the
1.1 kb rat PF4 promoter followed by a 1.7 kb fragment of the humanβ-globin gene [24,25], was modiﬁed by cloning a SpeI linker (NEB,
Ipswich, MA) into the restriction site BsgI. The fragment containing
β-globin gene was removed by NcoI-SpeI digestion and substituted
by the C3G fragment excised from pSKNco-C3G to generate plasmid
PF4-C3G.
The DNA fragment containing mutant C3GΔCat was obtained from
plasmid pLTR2C3GΔCat [23] by digestion with BamHI and ClaI and
inserted into plasmid pSP72 (Promega). Then, the C3GΔCat fragment
was removed from this construct with HindIII and BglII and cloned
into pBluescriptSK-NcoI to create pSKNcoI-C3GΔCat. C3GΔCat was ﬁ-
nally excised from this construct with NcoI-SpeI and cloned into PF4-
Globin containing the SpeI linker. The resulting construct was named
PF4-C3GΔCat.
A 1765 bp HindIII-EcoICRI LoxP ﬂanked, Eukaryotic Neomycin Se-
lection Cassette (LoxP-PGK-Neo-LoxP) (supplied by GenOway, Lyon,
France) was inserted into HindIII-SmaI sites of pSP72. From this con-
struct, the LoxP-PGK-Neo-LoxP cassette was excised as a KpnI-XhoI
fragment and inserted into the unique KpnI-XhoI restriction sites of
PF4-C3G and PF4-C3GΔCat to generate ﬁnal plasmids PF4-C3G-LN
and PF4-C3GΔCat-LN (Figs. S1, 1B). The PF4-C3G-LN and PF4-
C3GΔCat-LN constructs were linearized by digestion with PvuI/KpnI.
In this process, a 1.5 kb fragment containing the bacterial ampicillin
resistance gene was eliminated. The respective 8.2 kb and 7.8 kb
resulting fragments were puriﬁed by electroelution followed by etha-
nol precipitation and used for ES cell electroporation. GenOway per-
formed the generation of chimeras by blastocyst injections of stable
ESC clones using GenOways's Safe DNA transgenesis technology™.
2.2. Genotyping of transgenic mice by PCR
Genomic DNA was puriﬁed from lysed tails by precipitation with
5 M NaCl and ethanol (protocol based on [26]). Then, for Southern
blot analysis it was digested with BamHI to obtain a fragment of
3.6 kb or 5.3 kb from C3G or C3GΔCat constructs respectively, which
were detected using a radioactively labeled 740 bp EcoRI probe, pro-
duced by digestion of PF4-C3G-LN construct (Fig. 1B, C). In addition, ge-
nomic DNA ampliﬁcation was performed by polymerase chain reaction
(PCR) using the following primers: A1 (sense): 5′-ACCACATGGCAGTC-
AAACTCACAGC-3′ and C1 (antisense): 5′-TCTTCTGCCTTTGAGACCT-
GGAAGC-3′ to get a fragment of 847 bp (Fig. 1A, B and D). Primer A1
aligns within the PF4 promoter fragment, whereas primer C1 aligns
within the second exon of C3G gene. PCR conditions were: 94 °C, 45 s;
57 °C, 45 s; 72 °C, 80 s; 40 cycles.
2.3. Platelet puriﬁcation for RNA analysis
Blood (0.5–1 ml) was collected by retro-orbital bleeds from anes-
thetized mice (156 mg/kg ketamine, 6 mg/kg valium and 150 μg/kg
atropine in 0.9% NaCl) and used to prepare platelet‐rich plasma
(PRP) upon treatment with 200–400 μl of acid citrate-dextrose
(ACD) anticoagulant solution (80 mM trisodium citrate, 52 mM citric
acid, 180 mM glucose). The PRP was isolated by spinning the anti-
coagulated blood at 200 g, 20 min at RT. This PRP was centrifuged at
3160 g for 10 min to obtain the platelet pellet. Remaining red cells
were eliminated by a brief incubation of the pellet with 1% ammoni-
um oxalate. After two additional washes in PBS, the platelet pellet
was resuspended in RLT lysis buffer from RNeasy kit (QIAGEN) follow-
ing the manufacturer speciﬁcations for total RNA extraction.
2.4. Semiquantitative RT-PCR
cDNA from transgenic and control platelets was obtained from
RNA using SuperScript® II Reverse Transcriptase (Invitrogen) and
ampliﬁed by PCR to determine C3G expression using speciﬁc primers
corresponding to different human C3G exons: Ex3 Forward (F): 5′-
Fig. 1. Genomic analysis of PF4-C3G-LN and PF4-C3GΔCat-LN constructs. (A) Partial sequence of PF4 promoter and C3G gene (bold), common to both PF4-C3G-LN and PF4-
C3GΔCat-LN constructs. Primers A1 and C1, used in mice genotyping, are shadowed and underlined. BamHI, XbaI, NheI and NcoI restriction sites are shadowed. Nucleotides in italic
correspond to an intronic sequence present in the constructs. Consensus Kozak sequence is underlined. (B) Schematic representation of the linearized PF4-C3G-LN and PF4-
C3GΔCat-LN constructs showing relevant restriction enzymes, the position of A1 and C1 primers and the location of the 740 bp EcoRI probe used in the Southern blot analysis.
The size of the BamHI fragments detected by the probe is indicated. (C) Screening of transgenic clones by Southern blot with genomic DNA (20 μg) extracted from the indicated
C3G and C3GΔCat clones. The arrows point to the position of the 3.6 kb and 5.3 kb bands detected with the radiolabeled EcoRI probe. Clones selected for this work are marked
with an asterisk. (D) Screening of C3G-6A6 positive clones by PCR analysis of genomic DNA extracted from the indicated clones. Oligonucleotides A1/C1 detected a band of
847 bp in the transgenic clones, while oligonucleotide pair 2F/3R ampliﬁed a 252 bp band, corresponding to exons 2–3 of the human transgene. In addition, oligonucleotides
2F/3R ampliﬁed a 715 bp band in the controls, corresponding to mouse genomic DNA, which includes intron 2. Positive clones are highlighted with an asterisk.
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ATTCGAGGATC-3′; Ex5R: 5′-CTTCACTCCATCCAGCACA-3′; Ex7F: 5′-
AGCAGAGCTCCCCCTGA-3′; Ex8F: 5′-CCTCCACCAGCATTGACAC-3′; Ex9R:
5′-CTAGTGTTTCACAGCTTGTGTT-3′; Ex10F: 5′-ACCACTATGATCCCGACT-
ATG-3′; Ex12R: 5′-TCACTGCCGTCTCTGCTG-3′; Ex15F: 5′-GATTTGGTG-
TTGTACTGCGAG-3′; Ex17R: 5′-CCTGGCTGCTACCCCC-3′; Ex22F: 5′-
GGCCTGGCCGAGTACT-3′; Ex24R: 5′-TGCTGGAAGCAGCGCATG-3′. The
ampliﬁed fragments were normalized against the mouse gene CD41, a
platelet speciﬁc internal control, using primers: mCD41-F1: 5′-ATGC-
GGGCTCTCAGCAACATTG-3′ and mCD41-R1: 5′-TTGCCACAGGCAACAT-
CACGAC‐3′. The conditions for PCR were: 94 °C, 45 s; 55 °C, 45 s; and
72 °C, 80 min for 35 cycles. Densitometric analysis of the bands was per-
formed using Image J (Image Processing and Analysis in Java) free
software.
2.5. Megakaryocytic differentiation
Freshly isolated bone marrow cells from femurs of 6–8 week-old
mice were cultured in RPMI supplemented with 20% horse serum
and maintained at 5% CO2 and 33 °C. Megakaryocytes were differenti-
ated from bone marrow cultures by addition of 50 ng/ml throm-
bopoietin (TPO, CellGenix) to promote megakaryopoiesis. After
7 days, cells in suspension were collected and used to prepare protein
extracts or total RNA as described above.2.6. Bleeding time
Measurements were made in 3 week-old mice at weaning (before
genotyping) and in the same mice at 6-month age. A 5 mm section of
the tail tip from anesthetized mice was transected, and the tail was
immersed in 37 °C PBS to score time to cessation of blood ﬂow.
2.7. Flow cytometric analysis of C3G expression and platelet activation
Platelet activation was determined by ﬂow cytometry using FITC Rat
anti-mouse CD62P antibody (BD Pharmingen) to detect P-selectin ex-
pression on the surface andAlexa Fluor®488 labeled ﬁbrinogen (Molec-
ular Probes), which selectively binds to the high afﬁnity conformation of
the αIIbβ3 integrin. Alternatively, we measured integrin activation
using PE-labeled Rat anti-mouseαIIbβ3 (JON/A clone) antibody (Emfret
Analytics) [27]. Blood (50 μl) was collected from the retro-orbital plexus
of anesthetized mice with a heparinized glass capillary into 2 ml tubes
containing 200 μl of TBS/heparin (20 mM Tris–HCl, 137 mM NaCl, pH
7.3, 20 U/ml heparin). Heparinized bloodwas diluted 1:6 withmodiﬁed
Tyrode's Hepes buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl,
12 mM NaHCO3, 20 mM Hepes [N-2-hydroxyethylpiperazine‐N′-2-
ethanesulfonic acid], pH 7.0) containing 5 mM glucose, 0.35% bovine
serum albumin (BSA), and 1 mM CaCl2. Diluted blood was washed by
spinning 5 min at 1300 g and suspended in the same buffer. Finally,
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together with appropriate ﬂuorophore-conjugated monoclonal anti-
bodies or ﬁbrinogen for 15 min at room temperature and directly ana-
lyzed on a FACSCalibur (Becton Dickinson). PMA (2 μM), α-thrombin
(0.2 U/ml or 1 U/ml) and ADP (10 μM) were used as agonists of platelet
activation [28]. For analysis of C3G expression Tyrode's Hepes buffer-
washed blood, prepared as above, was incubated with saturating
amounts of FITC-labeled CD41 for 20 min in the dark. After two washes
in PBS/1% BSA/0.1% Na-azide, blood was ﬁxed in 200 μl of Leucoperm™
Reagent A (AbD Serotec) at room temperature for 15 min. After wash-
ing with PBS/1% BSA, ﬁxed blood was permeabilized and stained for
C3G by incubation with Leucoperm™ Reagent B (AbD Serotec) and rab-
bit anti-C3G antiserum #1008 [23,29] for 30 min at RT. After washing
twice with PBS/1% BSA, platelets were incubated with saturating
amounts of anti-rabbit-Cy5 for 20 min in the dark, washed again
twice and resuspended in 400 μl PBS before ﬂow cytometric analysis.
FlowJo 9.1 (Tree Star, Inc. Ashland, OR) software program was used
for data analysis.2.8. Platelet aggregation assays
Platelet aggregation was measured in a ﬁnal volume of 800 μl of
blood diluted to 1:2 with HEPES buffer, using a Chrono-Log
aggregometer (Haverton, USA). Samples were incubated at 37 °C
under constant stirring and, after 5 min, 5 μg/ml collagen (Chrono-
Log) was added. The extent of platelet aggregation was deﬁned arbi-
trarily as the percent of increase of electrical resistance between the
two immersed wires of the electrode probe. For ADP-, PAR-4 recep-
tor‐speciﬁc agonist, GYPGKF (PAR4) and PMA-induced platelet ag-
gregation, a Multiplate Aggregometer (Verum Diagnostica GmbH)
was used. Citrated blood (175 μl) was diluted 1:2 in 0.9% saline solu-
tion, containing 62.5 mM CaCl2, and incubated at 37 °C under con-
stant stirring. After 3 min, 6.6 μM ADP, 10 μM PMA, 1 μM PMA or
0.66 mM PAR4 was added and aggregometry was monitored for
6 min. The extent of platelet aggregation was measured as the in-
crease in impedance generated by the attachment of platelets onto
the Multiplate sensor, which is transformed into arbitrary aggrega-
tion units.2.9. Rap1 activation assay
Activation of Rap1 was evaluated essentially as described previ-
ously [30] using GST-RalGDS RBD immobilized on Glutathione-
Sepharose, which is known to bind speciﬁcally and selectively the
GTP-bound form of Rap1B. Brieﬂy, same volume of PRP per assay,
containing about 5–10×107 mouse platelets, were stimulated at
room temperature with 0.2 U/ml α-thrombin for 1 min or 0.2 μM
PMA for 5 min. When indicated, platelets were pretreated with
5 μM bisindolylmaleimide, 1 min before PMA stimulation. Platelets
were then lysed for 10 min at 4 °C with equal volume of 2× RIPA
modiﬁed lysis buffer (100 mM Tris–HCl, pH 7.5; 400 mM NaCl, 2%
NP-40, 5 mM MgCl2, 2% glycerol, 2 mM Na3VO4, 50 mM NaF, 2 mM
PMSF, 2 μM aprotinin, 2 μM leupeptin). Glutathione‐agarose beads
prebound to RalGDS RBD fused to GST were washed with ice-cold
lysis buffer and 20 μl bead volume was added to cell lysates and incu-
bated for 45 min at 4 °C. The precipitates were collected by brief cen-
trifugation, washed three times with 1× RIPA buffer, and ﬁnally
resuspended in 25 μl of SDS sample buffer. Precipitated GTP-Rap1
was separated by SDS-PAGE and detected by immunoblotting with
anti-Rap1mAb (610196) from BD Biosciences. Total Rap1 present in
platelet lysates was determined in a 20 μl of lysate sample, removed
prior to bead addition, by Western-blot analysis of Rap1. Fold stimu-
lation of active Rap1 was determined by densitometry using Image J
free software.2.10. Flow cytometric analysis of neutrophil content
The percentage of neutrophils in whole blood was determined by
ﬂow cytometry using antibodies against the granulocyte speciﬁc
markers Ly-6G/6C (Gr1) and CD11b (Mac1) (BD Pharmingen). Brief-
ly, EDTA-anticoagulated blood (100–150 μl) was incubated for
30 min with 12 ml ice-cooled red blood cells lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, 10 mM EDTA pH 7.4) to eliminate the erythro-
cytes. After a 10 min centrifugation, blood cells were washed with
cold PBS containing 1% fetal calf serum (FCS). Cells were resuspended
in 150–200 μl PBS/1% FCS and incubated with excess of antibodies for
20 min at 4 °C in the dark.
2.11. Evaluation of blood cellularity
White blood cells and platelet counting was determined from
EDTA-anticoagulated blood (30 μl) using a hemocytometer (Hemavet
Counter HV950FS).
2.12. Statistical analysis
Data are represented as mean±SEM. As comparisons were made
between two experimental groups, an unpaired Student's t-test was
used. Results were considered signiﬁcant when pb0.05.
3. Results
3.1. Generation of transgenic mouse models expressing C3G or mutant
C3GΔCat under the PF4 gene promoter
C3G and C3GΔCat mutant (lacking the last 439 bp of full-length
C3G catalytic domain) [23] were cloned into plasmid PF4-Globin to
speciﬁcally direct transgene expression to megakaryocytes and plate-
lets [24,25,31]. To do so, the fragment carrying the β-globin gene was
replaced by C3G- or C3GΔCat-fragments. A LoxP-PGK-Neo-LoxP cas-
sette was also inserted in both constructs. The resulting plasmids
were named PF4-C3G-LN and PF4-C3GΔCat-LN, respectively (Fig.
S1), where the transgenes were under the control of the PF4 gene
promoter (Fig. 1A, B). The constructs also contain a Kozak consensus
sequence to ensure a correct initiation of translation (Fig. 1A). Both
constructs were used to generate transgenic mice through blastocyst
injection of stable ESCs (performed by GenOway Company, Lyon,
France). We selected two C3G transgenic lines (2C1 and 6A6) and
one C3GΔCat line (8A3), with correct integration of the transgenes
(Fig. 1C, D).
3.2. Characterization of C3G transgene expression
Semiquantitative RT-PCR analysis of total RNA from puriﬁed plate-
lets, using primers for different C3G exons, revealed a signiﬁcant C3G
over-expression in transgenic platelets as compared to those from
wild type mice (Fig. 2A). Platelets from heterozygous animals also
showed a clear increase in C3G expression (Fig. 2A). An evident C3G
over-expression (~2–4 fold increase) was also detected in platelets
from C3GΔCat transgenic animals. As expected, we did not observe
any increase in the expression of exons 22–24 in C3GΔCat mutant,
as this region was deleted (Fig. 2B). Platelet speciﬁc CD41 gene
(GPIIb, encoding theαIIb subunit of platelet integrinαIIbβ3) was am-
pliﬁed as a control of platelet integrity and loading. C3G over-
expression was also observed in TPO-differentiated megakaryocytes
from the transgenic C3G-2C1 line (Fig. 2C), but no C3G over-
expression was detected in other tissues such as liver or kidney
(Fig. S2), in agreement with the restricted expression of the trans-
genes to megakaryocytes and platelets [24].
Fig. 2. Expression of C3G transgenes. C3G expression was analyzed by RT-PCR in puriﬁed platelets from (A) wild type (−), homozygous (+) or heterozygous (±) full-length C3G
(6A6 line) or (B) C3GΔCat transgenic mice (8A3 line) and their corresponding wild type siblings. Each panel shows the expression of the indicated C3G exons, which were ampliﬁed
with forward and reverse oligonucleotides located in the ﬁrst and last exons respectively. K: cDNA from K562 cells, P1: pLTR2C3G plasmid, P2: PF4-C3GΔCat-LN plasmid, C: PCR mix
without cDNA, M: male, F: female. Relative densitometric values are shown. wt: wild type, tg: transgenic. (C) TPO-differentiated bone marrow cells RNA, from a C3G-2C1 transgenic
mouse and a wild type sibling, was isolated and reverse transcribed to generate cDNA. PCR was subsequently conducted using primer sets that speciﬁcally amplify exons 3 to 5.
Expression of CD41 was determined as loading control in panels A to C. (D) TPO-differentiated bone marrow total cell lysates were obtained from wild type, transgenic C3G-
2C1 and transgenic C3GΔCat-8A3 mice. The panel is a representative Western blot showing transgenic C3G and C3GΔCat protein expression, together with the endogenous
C3G, detected with anti-C3G (H-300) antibody (Santa Cruz Biotechnologies, sc-15359) and normalized with anti-β-actin antibodies (Sigma, A5441) and anti-Integrin αIIb
(B-10) antibodies (Santa Cruz Biotechnologies, sc-166599). (E) Speciﬁcity of the intracellular C3G detection in platelets by ﬂow cytometry; the plot represents a double label-
ing, CD41-FITC/anti-rabbit-Cy5, of peripheral blood cells incubated with or without rabbit anti-serum C3G #1008. (F) Representative histograms showing double CD41-FITC/
C3G-Cy5-labeled blood cells from a transgenic 2C1 (left panel), 6A6 (middle panel) or 8A3 (right panel) mouse and their corresponding sibling controls. The percentage of
C3G expression in the platelets gated by SSC/CD41-FITC is shown. Graphs are representative of 5 independent experiments. wt: wild type, tg: transgenic.
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in lysates of TPO-differentiated megakaryocytes, as compared to
wild type mice (Fig. 2D). Transgene expression was also detected in
platelets by ﬂow cytometry (cells positive for CD41 and C3G-Cy5), al-
though expression levels showed great variability among individuals
(Fig. 2E, F).3.3. C3G and C3GΔCat transgenes alter the hemostatic function of
platelets
To study the involvement of C3G on hemostasis, we performed
tail-bleed assays in transgenic mice and their wild type siblings at
weaning and 6 months later in the same animals. At weaning, tgC3G
animals showed statistically signiﬁcant shorter bleeding times than
control animals (mean±SEM: 44.0±4.5 s vs 64.2±6.7 s, respective-
ly, p=0.024). In contrast, the mean time for bleeding cessation in
tgC3GΔCat animals was signiﬁcantly higher than in their corresponding
sibling controls (125.8±17.7 s vs 86.8±7.5 s, respectively, p=0.0052,
Fig. 3A). The differences were reinforced after 6 months, especially for
tgC3GΔCat mice (74.1±11.0 s in tgC3G vs 122.1±17.3 s in wild type;
p=0.0275 and 254.1±24.8 s in tgC3GΔCat vs 89.3±10.2 s in wild
type; p=0.0000085, Fig. 3B). The same tendency was observed in the
blood mass obtained (data not shown). The hemostatic disorder ob-
served in the transgenic animals was not due to defects in platelet for-
mation, as the platelet number was similar in mice of the differentgenotypes (Table 1). Additionally, there were no signiﬁcant changes
in hematocrit and hemoglobin levels in transgenic animals (Table S1),
whichmeans that C3GΔCat transgenic animals do not suffer from spon-
taneous hemorrhaging or anemia. These results indicate that C3G par-
ticipates in platelet clotting through a mechanism dependent on its
catalytic domain, which might involve the participation of Rap1 in this
effect.3.4. C3G and C3GΔCat transgenes modify the response of platelets to
agonists
To determine whether the hemostatic defects observed in the
transgenic animals were caused by impaired platelet function, we in-
duced platelet activation by using several agonists known to activate
Rap1, including thrombin, PMA and ADP. We determined P-selectin
expression on the surface, as a measure of agonist-induced degranu-
lation, and integrin αIIbβ3 activation, as a measure of inside-out sig-
naling. As shown in Fig. 4A, platelets from transgenic C3G mice
showed higher expression of P-selectin on the surface in response
to thrombin and PMA, while a signiﬁcant reduced response to these
agonists was observed in platelets from C3GΔCat transgenic animals
as compared to wild type platelets. Similarly, platelets from C3G
transgenic mice showed higher αIIbβ3 binding to Alexa Fluor® 488-
conjugated ﬁbrinogen in response to thrombin and ADP, while
integrin from C3GΔCat-expressing platelets was less responsive to
Fig. 3. Transgenic mice showed altered hemostasis. (A) Tail-bleed assays performed on
transgenic C3G (tgC3G) and transgenic C3GΔCat (tgC3GΔCat) mice and their wild type
controls (wt1 and wt2 respectively) at weaning. (B) The experiment was repeated in
the same animals after 6 months. The box plots represent the bleeding times of
30–40 animals of each genotype. The median values are shown.
Table 1
C3G transgenes do not modify platelet number.
Genotype Sex NA Plt (×103/μl) mean±SEM
2C1+ M 25 1145±101
F 21 1059±59
2C1− M 11 961±32
F 12 1020±51
6A6+ M 31 1038±31
F 37 996±35
6A6− M 33 1120±48
F 29 974±35
8A3+ M 20 1194±49
F 24 1063±51
8A3− M 13 1191±68
F 14 1000±56
Platelet counts in transgenic mice and wild type siblings of the different genotypes.
Counts were performed using a Hemavet Counter HV950FS. p Values for transgenic
animals versus wild type siblings are as follows: 0.12 for 2C1 males, 0.33 for 2C1
females, 0.08 for 6A6 males, 0.34 for 6A6 females, 0.48 for 8A3 males, 0.27 for 8A3
females. NA: number of animals. Plt: platelets.
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obtained with the JON/A antibody regarding thrombin activation
(data not shown). Expression of αIIbβ3 was similar in transgenic
and control platelets, as assessed by ﬂow cytometry with anti-
CD41-APC (data not shown). Under our experimental conditions,
PMA barely stimulated αIIbβ3 integrin, while ADP hardly affected
surface P-selectin levels, as previously observed by other authors
[28]. Additionally, platelet aggregation was impaired in tgC3GΔCat
platelets in response to 5 μg/ml collagen. In contrast, tgC3G platelets
showed increased aggregation as compared with platelets from
wild-type mice (Fig. 4C, D). Similar results were obtained in response
to ADP, PMA and PAR4 peptide (Fig. 4E and Fig. S3). All these in vitro
experiments are in agreement with the tail-bleed assay and suggest
that C3G participates in PMA, thrombin, ADP and collagen-mediated
platelet activation, possibly through Rap1. Moreover, ﬁbrinogen-
binding and aggregation assays indicate that C3G plays a role in the
inside-out activation of αIIbβ3 integrin.
3.5. Activation of Rap1 in the transgenic platelets: Rap1 mediates the
effect of C3G
All the above results indicate that C3G overexpression enhances
Rap1-mediated integrin activation. In contrast, C3GΔCat transgene
would behave as a C3G dominant negative mutant, inhibiting Rap1.
To conﬁrm this hypothesis, we performed a Rap1 activation assayon freshly isolated PRP stimulated with 0.2 U/ml α-thrombin for
1 min, conditions that have been widely validated [5,12]. Basal Rap1
activation was increased in tgC3G mice as compared to that in wild
type siblings, while tgC3GΔCat platelets showed lower Rap1-GTP
basal levels than control animals (Fig. 5A). Similarly, Rap1 activation
by thrombin was stronger in tgC3G platelets than in wild type plate-
lets, while thrombin-stimulated tgC3GΔCat platelets showed lower
Rap1-GTP levels than wild type siblings, in agreement with data in
Fig. 4.
It has been described that, under aggregating conditions, thrombin-
induced Rap1 activation is rapidly downregulated [5]. When the exper-
iment was performed under these conditions (platelets stirred during
incubation), we observed a faster Rap1 downregulation in tgC3G plate-
lets and a signiﬁcant lower dowregulation in tgC3GΔCat platelets as
compared to their respective controls (Fig. 5B). All these results indicate
that transgenic C3G and C3GΔCat expression upregulates or down-
regulates Rap1 activation, respectively, which is in agreement with
their effects in platelet aggregation.3.6. C3G is a relevant mediator in the PKC pathway leading to Rap1
activation
Platelet aggregation stimulated by PMA was not affected in
CalDAG-GEF1 KO platelets [12], which suggests the existence of
other Rap1 GEFs playing a role in PKC-mediated Rap1 activation. To
assess whether C3G could contribute to the PKC-Rap1 pathway in
platelets, we performed a Rap1 assay on PRP stimulated with 0.2 μM
PMA for 5 min in the presence or absence of the PKC inhibitor
bisindolylmaleimide. Results in Fig. 6A show that, PMA stimulates
Rap1, in agreement with previous reports [5]. This stimulation was
much higher in C3G transgenic platelets than that inwild type platelets,
which is in agreementwith the results shown in Fig. 4 and suggests that
C3G participates in the platelet PKC pathway. Furthermore, the increase
in PMA-induced Rap1 activation observed in C3G transgenic platelets
was almost completely abolished by bisindolylmaleimide, which indi-
cates that PKC-induced Rap1 activation is mediated by C3G. This was
conﬁrmed by the absence of Rap1 activation in response to PMA in
tgC3GΔCat platelets. These results are supported by platelet activa-
tion assays monitoring P-selectin expression on the surface. Fig. 6B
shows that the increase in P-selectin expression observed in C3G
transgenic platelets stimulated with PMA was prevented upon pre-
treatment with bisindolylmaleimide. In contrast, platelet activation
by thrombin was only partially inhibited by bisindolylmaleimide
(Fig. 6B), in agreement with the existence of thrombin-induced
PKC-dependent and independent pathways [5]. Therefore, we have
Fig. 4. Transgenic platelets are differently activated in response to agonists. Washed blood from transgenic and wild type mice was stimulated with PMA (2 μM), α-thrombin (0.2 U/ml)
or ADP (10 μM) and incubated with (A) anti-CD62P-FITC antibody to determine the percentage of platelets expressing P-selectin on the surface or (B) with Alexa Fluor® 488-
conjugated ﬁbrinogen to determine the percentage of platelets with activated αIIbβ3 integrin. The histograms represent the mean±SEM of 10 independent experiments. *pb0.05,
**pb0.01; values are relative to the corresponding control platelets for each genotype. wt: wild type, tg: transgenic. (C) Representative aggregation traces from wild type, tgC3G
and tgC3GΔCat mouse platelets treated with collagen (5 μg/ml). Arrows indicate the addition of agonist. (−) Lines: non-stimulated platelets, (+) lines: collagen-stimulated platelets.
(D) Histograms represent the mean±SEM of the aggregation percentage (as a measure of electrical resistance) of collagen-treated platelets from 3 mice of each genotype. *pb0.05,
**pb0.01 vs wild type. Values for wild type animals include one animal per line (2C1, 6A6 and 8A3). (E) Histograms represent the mean±SEM of the aggregation values (relative
units) of ADP (6.6 μM), PMA (10 μM and 1 μM) and PAR4 (0.66 mM)-treated platelets from 3 to 5 mice of each genotype. *pb0.05; **pb0.01; ***pb0.001 vs wild type.
Fig. 5. Rap1 is differentially activated in C3G and C3GΔCat transgenic platelets. Platelets from tgC3G (2C1 and 6A6) or tgC3GΔCat (8A3) mice and their corresponding wild types
were unstimulated (−) or stimulated (+) with 0.2 U/ml of α-thrombin for 1 min under (A) nonaggregating or (B) aggregating conditions. Platelets were then lysed, and activated
Rap1 was isolated by binding to GST-RalGDS-RBD and detected by immunoblotting with anti-Rap1 antibodies. The results shown are representative of three experiments with sim-
ilar results. The ration Rap1-GTP/Total Rap1 is indicated beneath the blots. wt: wild type, tg: transgenic, TH: thrombin.
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Fig. 6. C3G participates in PKC-mediated Rap1 activation. (A) Platelets from tgC3G (6A6) or tgC3GΔCat (8A3) mice and their corresponding wild types were unstimulated (−) or
stimulated (+) with 0.2 μM PMA for 5 min in the presence or absence of 5 μM bisindolylmaleimide, which was added 5 min prior PMA stimulation. Platelets were then lysed, and
activated Rap1 was isolated by binding to GST-RalGDS-RBD and detected by immunoblotting with anti-Rap1 antibodies. The ration Rap1-GTP/Total Rap1 is indicated beneath the
blots. wt: wild type, tg: transgenic. BIS: bisindolylmaleimide. (B) Washed blood from transgenic and wild type mice was stimulated with PMA (2 μM), α-thrombin (1 U/ml) and
incubated with anti-CD62P-FITC antibody to determine the percentage of platelets expressing P-selectin on the surface. The histograms represent the mean±SEM (n=5).
*pb0.05, **pb0.01 versus unstimulated CT; †pb0.05, ††pb0.01 versus the corresponding bar in WT; ‡‡pb0.01 versus tg6A6-PMA. Control values were normalized to 1 for a better
appreciation of the effect of the treatments within the different lines. wt: wild type, tg: transgenic. BIS: bisindolylmaleimide.
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tion by PKC.
3.7. C3G transgenic mice showed an increase in neutrophils
As mentioned, we found no differences in the number of platelets
between transgenic and control animals (Table 1). However,
hemocytometric analysis showed a signiﬁcant increase in neutrophils
in tgC3G mice as compared with control siblings (Table 2). This result
was veriﬁed by ﬂow cytometry using granulocyte speciﬁc markers Ly-
6G/6C (Gr1) and CD11b (Mac1) (Fig. 7A, B). In contrast, no signiﬁcant
effect was observed in C3GΔCat transgenic platelets. Moreover, no
transgenic expression was detected in puriﬁed granulocytes obtainedTable 2
C3G transgene increases the number of neutrophils in peripheral blood.
Age (months) tgC3G Wild type p Value
4 25.35±8.49 20.96±5.18 0.033
6 27.06±7.94 22.07±5.06 0.024
8 29.59±7.68 25.24±5.94 0.033
10 31.00±8.54 24.76±6.27 0.064
Percentage of neutrophils (mean±SEM) in C3G transgenic mice and wild type siblings.
Measures were performed at different ages in 35 mice positive for C3G transgene, (2C1
and 6A6 lines) and 21 wild type mice, using a Hemavet Counter HV950FS. p Values for
transgenic versus wild type neutrophil percentage are indicated.from hydrocortisone-driven bone marrow differentiation (data not
shown), in agreement with the speciﬁc expression of the PF4 promot-
er in megakaryocytes/platelets. Therefore, the increase in the per-
centage of neutrophils must be an indirect effect of the over-
expression of C3G in platelets.
4. Discussion and conclusions
In this paper we demonstrate for the ﬁrst time the involvement of
C3G in platelet function. To do so, we have generated C3G transgenic
mice in which the human C3G gene is under the megakaryocytic/
platelet speciﬁc PF4 gene promoter. The backbone plasmid used in
the generation of the transgenic constructs has been widely validated
for its speciﬁc expression in megakaryocytes and platelets [24,25,31].
Platelets are non-nucleated cell fragments. This guarantees that
our RNA preparations are free of genomic DNA contaminant. In ad-
dition, in the PCR analysis each pair of primers ampliﬁed several
exons to ensure a cDNA origin of the template. The oligonucleotides
used in the genotyping and expression characterization of the trans-
genic animals correspond to the human C3G sequence. In fact, we
have detected endogenous C3G expression in human platelets with
our sets of primers (data not shown). Thus, it is likely that most of
the detected C3G would correspond to the human transgene. Never-
theless, considering the high homology between human and mouse
sequences (87%), the mouse C3G endogenous gene is also detected
in the wild type controls. Over-expression of the C3G transgenic
Fig. 7. C3G transgenic mice showed increased neutrophil counts. (A) Representative contour plots showing the percentage of double Gr1-FITC/Mac1-PE labeled cells in lysed
blood of a 6A6 transgenic mouse and a wild type sibling. (B) Histograms represent the superimposed proﬁles of Gr1-FITC- (left panel) and Mac1-PE- (right panel) labeled
cells in the 6A6-tg and 6A6-wt mice from the above plots. Numbers indicate the percentage of Gr1- and Mac1-expressing cells respectively. Graphs are representative of the
analysis of more than 20 different mice from each genotype. Similar results were found with the 2C1 transgenic line. wt: wild type, tg: transgenic.
1374 S. Gutiérrez-Herrero et al. / Biochimica et Biophysica Acta 1823 (2012) 1366–1377proteins is evident, both in megakaryocytes and platelets and their
levels are sufﬁcient to modify Rap1 activation and platelet function.
The results obtained with the full-length C3G transgene are
strengthened by the use of two different chimeric lines. Furthermore,
our results with this transgenic model are reinforced by the use of a
dominant negative (DN) version of the transgene that blocks Rap1 ac-
tivation and, consequently, platelet function. This DN function is
clearly demonstrated by the decrease in Rap1-GTP levels observed
in platelets from tgC3GΔCat (8A3) strain stimulated with thrombin
(Fig. 5) and PMA (Fig. 6). This C3GΔCat mutant (which lacks the es-
sential aminoacids for the GEF function) would act by sequestering
upstream elements important for the activation of Rap1 by other
GEFs. This hypothesis agrees with results from Fig. 4, showing a
lower response to agonists in C3GΔCat platelets than that in wild
type platelets. This C3G DN transgene (C3GΔCat) has been previously
demonstrated to act as a negative mutant in other systems [29,32]. In
all of our experimental approaches, the C3GΔCat mutant effect was
opposite to that of the full C3G transgene. This clearly demonstrates
that the effect of the C3G transgene is a direct effect on Rap1 and
not a random or artifactual effect.
Results derived from blood clotting experiments demonstrate
that C3G plays a relevant role in hemostasis. Hence, while control
mice stop bleeding within the ﬁrst 2 min, some of the C3GΔCat
chimeras bled longer than 8 min, limit time of the experiment. In
contrast, most C3G transgenic mice ceased bleeding within the
ﬁrst minute. These results are in agreement with the role of
Rap1b in the regulation of the afﬁnity state of integrin αIIbβ3 in
mouse megakaryocytes and platelets [4,33]. Furthermore, our re-
sults indicate that C3G participates, at least, in thrombin, PMA,
ADP and collagen-mediated platelet activation. In platelets, α-
thrombin induces an early Rap1 activation, through a calcium-
mediated pathway, independent of PKC activation. This is followed
by a second activation phase mediated by PKC and, partially, by
integrin αIIbβ3 [5,34].So far, CalDAG-GEFI is the only Rap1 GEF with a proved role in
platelet function [12–14,35]. CalDAG-GEFI knockout mice are severe-
ly deﬁcient in platelet aggregation in response to low thrombin and
partially impaired in response to low PMA concentration. However,
CalDAG-GEFI knockout platelets are normally activated by high con-
centrations of these agonists (10×), and maintain a partial response
to collagen, indicating the existence of CalDAG-GEF1-independent
signaling pathways [12,14,36]. Here we show that, apart from
CalDAG-GEFI, C3G is also endogenously expressed in platelets (see
Fig. 2) and hence, it may play a physiological role. In fact, our results
showing an increased response to thrombin in tgC3G platelets and an
impaired response in tgC3GΔCat platelets, together with the opposite
effects of both transgenes over thrombin-mediated Rap1 activation,
indicate that C3G participates in a thrombin-Rap1 pathway in
platelets.
Additionally, based on our results showing an increase in PMA-
induced activation of tgC3G platelets, together with the fact that
platelet aggregation triggered by PMA is not impaired in CalDAG-
GEF1 KO platelets [12], it can be proposed a speciﬁc involvement of
C3G in the second (PKC-dependent) phase of Rap1 activation induced
by thrombin [5,14]. This is further reinforced by results in Fig. 6 show-
ing that PKC-mediated Rap1 activation is mainly dependent on C3G.
Hence, based on the results presented here and on with previous re-
sults showing the existence of CalDAG-GEFI and PKC independent
pathways for Rap1 activation [14], as well as participation of PKC in
the second phase of thrombin-mediated Rap1 activation [5], it is pos-
sible to propose a model where C3G could be a mediator in the
thrombin-stimulated pathways in platelets (Fig. 8). We can not ex-
clude the possibility that the increase in Rap1-GTP induced by throm-
bin in tgC3G platelets is, in part, a reﬂect of the higher basal Rap1-GTP
levels in these platelets. However, the levels of Rap1-GTP in PMA-
stimulated tgC3G platelets are higher than the sum of basal Rap-
GTP in tgC3G platelets and Rap1-GTP induced by PMA in wild type
platelets (Fig. 6A), which suggests an ampliﬁcation of the thrombin
Fig. 8. Schematic representation of thrombin-triggered pathways leading to αIIbβ3
activation in mouse platelets. C3G would participate in the PKC-mediated activation
of Rap1. PLC-β2: phospholipase C β2; PAR4: protease activated receptor 4; BIS:
bisindolylmaleimide, DAG: diacylglycerol; IP3: Inositol trisphosphate.
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better reﬂected in Fig. 6B, where all controls have been normalized,
and is also evident in the thrombin activation studies (Fig. 4A–B). In
addition, other RapGEFs with detectable expression in mouse plate-
lets [20] could contribute to PKC-dependent Rap1 activation, as
there is still some platelet aggregation in transgenic C3GΔCat plate-
lets stimulated with PMA.
ADP activates Rap1, both in human and mouse platelets [7–9,34].
So, our results showing an impaired response to ADP in tgC3GΔCat
platelets indicate that C3G would mediate, at least in part, this ADP-
induced Rap1 activation. We did not detect a signiﬁcant ADP-
induced activation of αIIbβ3 integrin with JON/A antibody (data not
shown). Nevertheless, ADP clearly activated ﬁbrinogen-binding to
αIIbβ3 integrin, which is in agreement with a synergistic effect be-
tween ﬁbrinogen and ADP [37]. The observed increase in integrin ac-
tivation in tgC3G platelets stimulated with thrombin, ADP or collagen
was not due to an upregulation of αIIbβ3 gene expression induced by
C3G, as we did not observe signiﬁcant differences, either in total
αIIbβ3 content (Fig. 2D) or in that present on the surface (data not
shown derived from cytometric analysis). Fibrinogen-binding and
collagen-mediated aggregation assays indicate that C3G participates
in the inside-out activation of αIIbβ3 integrin. In addition, C3G con-
tributes to collagen-mediated platelet activation probably through
glycoprotein GPVI, the main collagen receptor that activates Rap1 in
platelets [36,38,39].
It is well known that Rap1 protein levels increase during megakar-
yocyte maturation [40]. On the other hand, C3G silencing in the
megakaryoblastic cell line MEG-01 results in a decrease in total
Rap1 protein content (data not shown). This result is in agreement
with the proposed role for C3G in the differentiation and maturation
of megakaryocytes [3,41,42]. Despite this putative role of C3G, we
found no differences in platelet number between transgenic and
wild type animals, although this result is in agreement with the phe-
notype observed in Rap1b-null mice [4]. One potential explanation
would be the participation of C3G in the initial steps of the
megakaryopoiesis, but not in the ﬁnal maturation to platelets.
Transgenic full-length C3G, but not C3GΔCat mice showed a sig-
niﬁcant increase in the number of neutrophils. As expected, puriﬁed
neutrophils do not express transgenic C3G. This raises the possibility
of an indirect effect of C3G overexpression in platelets, which could
lead to the release of platelet-derived factors able to stimulate neu-
trophil development. It is known that platelets secrete chemokines
that attract neutrophils and activate neutrophil production of pro-
inﬂammatory cytokines [43]. For example, CXCL4 (PF4) can activate
neutrophils in the presence of appropriate co-stimuli such as tumornecrosis factor alpha (TNF-α). Therefore, it is reasonable to hypothe-
size that C3G could stimulate the production and release of one or
several platelet factors that stimulate neutrophil production. In sup-
port of this hypothesis resting C3G transgenic platelets displayed a
low, but signiﬁcant activation, as compared to control platelets (see
Fig. 4).
Results from our group and others support the involvement of
C3G in chronic myeloid leukemia (CML) [44–46]. CML chronic phase
is characterized by the presence of a high percentage of mature neu-
trophils in peripheral blood, which present high levels of CrkL phos-
phorylation, a constitutive C3G adaptor protein [47]. Moreover,
platelet functions such as aggregation and clot retraction are often ab-
normal in chronic myelogenous leukemia (CML) patients [48,49].
CrkL is also abnormally phosphorylated in platelets from CML pa-
tients [50], similar to that observed in neutrophils. Interestingly, and
in agreement with a putative role of C3G in neutrophils, Rap1a is ac-
tivated by a variety of stimuli involved in neutrophil functions [51].
Rap1a interacts with neutrophil NADPH oxidase [52] and stimulates
superoxide production during the oxidative burst [53]. Furthermore,
another Rap1 GEF, CalDAG-GEFI, has also been shown to play an im-
portant role in neutrophil function [13,35]. Based on that, our C3G
transgenic models would be interesting tools in order to study, in a
Bcr-Abl background, whether C3G plays a role in the initial steps of
CML development by inﬂuencing abnormal neutrophil production
and platelet function.
In conclusion, the work presented here shows for the ﬁrst time
that C3G plays a role in the regulation of platelet function and
opens a new perspective on C3G as a potential therapeutic target in
thrombotic disorders. Future studies will be conducted to determine
whether C3G participates in inside-out or/and outside-in signaling
and to dissect the speciﬁc signaling pathways that engage C3G in
the regulation of Rap1 activity in platelets. Finally, the C3G transgenic
mouse models will be useful to assess the potential role of C3G in
neutrophil development and function as well as in CML development.Funding
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